University of Connecticut Provost and Executive Vice President for Academic Affairs Mun Y. Choi announced the appointment of Dr. James Halpert as dean of the School of Pharmacy following a nationwide search. “This is truly an exciting period in UConn’s history, and we recognize the important role of the School of Pharmacy in conducting breakthrough research and implementing innovative training programs. We are excited that Dr. Halpert will lead the university’s School of Pharmacy as dean, and look forward to the school’s continued success and next level of accomplishment,” said Choi.
John Morris, Ph.D., interim dean of the School of Pharmacy, cited Halpert’s extensive research, administrative, and leadership experience in academia as great assets. “The school will greatly benefit from Dr. Halpert’s wealth of experience as it moves forward with the university’s Next Generation Connecticut initiative,” said Morris.
Halpert is thrilled to be making the move to Connecticut. “Exciting things are happening at UConn in both research and clinical practice. I look forward to leading the school and working with the faculty as we collaborate with the medical and scientific communities to advance healthcare throughout the drug discovery, delivery, and patient care process.”
Halpert comes from the University of California San Diego’s Skaggs School of Pharmacy and Pharmaceutical Sciences where he serves as professor and associate dean for scientific affairs. Prior to joining UCSD, Dr. Halpert was professor and chair of the Department of Pharmacology and Toxicology at the University of Texas Medical Branch, where he also served as director of the National Institute of Environmental Health Sciences Center in Environmental Toxicology, and interim director of the Sealy Center for Environmental Health and Medicine. He also held the Mary Gibbs Jones Distinguished Chair in Environmental Toxicology. Prior to joining the University of Texas, Dr. Halpert served for fifteen years on the faculty at the University of Arizona.
Dr. Halpert earned his Ph.D. in biochemistry from Uppsala University, Sweden in 1977, his M.S. in Toxicology from the Karolinska Institute, Stockholm, Sweden in 1978 and his B.A. in Scandinavian Languages from the University of California at Los Angeles in 1971.
In addition to his university leadership positions, Dr. Halpert served as editor of Drug Metabolism and Disposition, the primary scientific journal in his field of research, president and secretary-treasurer of The American Society for Pharmacology and Experimental Therapeutics, chair of the NIH Pharmacology Study Section, and as a member of the National Institute of General Medical Sciences Biomedical Research and Research Training Review Committee.
Dr. Halpert’s research for the past 35 years has focused on the structure and function of cytochromes P450 of the 2B and 3A subfamilies. This work has been funded continuously by the National Institutes of Health since 1985. He is a fellow of the American Association for the Advancement of Science. In 2010, Dr. Halpert was the recipient of the Bernard B. Brodie Award from the American Society for Pharmacology and Experimental Therapeutics.
Halpert will be joining the school on June 1st.